Received > mg/m equivalents of daunorubicin (see Appendix G for conversion table)
Received > mg/m equivalents of daunorubicin
Eligible for intensive cytarabine/daunorubicin (+) chemotherapy specified
Patients who have received >  mg/m^ daunorubicin equivalents; patients who relapse after receiving AAML/AAML therapy will be eligible for this study, provided they have not received any additional anthracyclines; NOTE: for the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine daunorubicin equivalents:\r\n* Doxorubicin (doxorubicin hydrochloride): \r\n* Mitoxantrone: \r\n* Idarubicin: \r\n* Epirubicin: .
Patients with prior allergy to daunorubicin and/or cytarabine
Predicted inability to tolerate standard induction chemotherapy with daunorubicin and cytarabine
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Patients who have previously had >  mg/m^ cumulative dose of daunorubicin or >  mg/m^ daunorubicin-equivalent anthracycline therapy (for example, from prior treatment of solid tumors)
Known hypersensitivity to cytarabine, daunorubicin or liposomal products
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Eligible for induction by daunorubicin + cytarabine.
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Relapsed patients:\r\n* Second or greater relapse OR\r\n* AML in first relapse AND has received >=  mg/m^ daunorubicin equivalents \r\n* NOTE: for the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine daunorubicin equivalents:\r\n** Doxorubicin: \r\n** Mitoxantrone: \r\n** Idarubicin: \r\n** Epirubicin: .
